Curcumin enhances temsirolimus-induced apoptosis in human renal carcinoma cells through upregulation of YAP/p53

Xu,Shan; Yang,Zheng; Fan,Yizeng; Guan,Bing; Jia,Jing; Gao,Yang; Wang,Ke; Wu,Kaijie; Wang,Xinyang; Zheng,Pengsheng; He,Dalin; Guo,Peng

doi:10.3892/ol.2016.5376

Curcumin enhances temsirolimus-induced apoptosis in human renal carcinoma cells through upregulation of YAP/p53

Authors:
- Shan Xu
- Zheng Yang
- Yizeng Fan
- Bing Guan
- Jing Jia
- Yang Gao
- Ke Wang
- Kaijie Wu
- Xinyang Wang
- Pengsheng Zheng
- Dalin He
- Peng Guo
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Reproductive Medicine, The First Affiliated Hospital, Xi'an Jiaotong University Medical School, Xi'an, Shaanxi 710061, P.R. China
Published online on: November 10, 2016 https://doi.org/10.3892/ol.2016.5376
Pages: 4999-5006
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Curcumin has frequently been used as a therapeutic agent in the treatment of various types of disease and is known to enhance the drug sensitivity of cells. In the present study, the combined effect of curcumin and temsirolimus treatment on apoptosis in human renal cell carcinoma (RCC) cells was investigated. Temsirolimus is an inhibitor of the mechanistic target of rapamycin signaling pathway and used in the first‑line treatment of metastatic RCC. It was demonstrated that curcumin combined with temsirolimus markedly induced apoptosis in RCC cells, however this effect was not observed following curcumin or temsirolimus treatment alone. Co‑treatment with temsirolimus and curcumin led to the activation of cleaved poly ADP‑ribose polymerase and caspase 3, upregulation of p53 expression and nuclear translocation, and downregulation of B‑cell lymphoma 2 protein expression. Furthermore, curcumin treatment was demonstrated to increase Yes‑associated protein (YAP) expression in a time‑dependent manner, which was concurrent with the curcumin‑induced expression pattern of p53 after 2 h. In addition, knockdown of YAP by small interfering RNA caused the attenuation of curcumin‑induced increased p53 expression in RCC cells. In conclusion, the present results indicate that combined curcumin and temsirolimus treatment has a synergistic effect on apoptosis in human RCC cells, through the activation of p53. Mechanistically, YAP is essential in the induction of p53 expression by curcumin. Furthermore, the results suggest that pre‑treatment or co‑treatment of cells with low concentration curcumin enhances the response to targeted drugs, and this presents a potentially novel and efficient strategy to overcome drug resistance in human RCC.

View Figures

View References

1	Frew IJ and Moch H: A clearer view of the molecular complexity of clear cell renal cell carcinoma. Annu Rev Pathol. 10:263–289. 2015. View Article : Google Scholar : PubMed/NCBI
2	Axelson H and Johansson ME: Renal stem cells and their implications for kidney cancer. Semin Cancer Biol. 23:56–61. 2013. View Article : Google Scholar : PubMed/NCBI
3	Kapoor A and Figlin RA: Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma. Cancer. 115:3618–3630. 2009. View Article : Google Scholar : PubMed/NCBI
4	Gerullis H, Ecke TH, Eimer C, Heuck CJ and Otto T: mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: A review. Minerva Urol Nefrol. 62:411–423. 2010.PubMed/NCBI
5	Tuorkey MJ: Curcumin a potent cancer preventive agent: Mechanisms of cancer cell killing. Interv Med Appl Sci. 6:139–146. 2014.PubMed/NCBI
6	Gao Y, Shi Q, Xu S, Du C, Liang L, Wu K, Wang K, Wang X, Chang LS, He D and Guo P: Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells. Int J Mol Sci. 15:15173–15187. 2014. View Article : Google Scholar : PubMed/NCBI
7	Rahmani AH, Al Zohairy MA, Aly SM and MA: Curcumin Khan: A potential candidate in prevention of cancer via modulation of molecular pathways. Biomed Res Int. 2014:7616082014. View Article : Google Scholar : PubMed/NCBI
8	Troselj KG and Kujundzic RN: Curcumin in combined cancer therapy. Curr Pharm Des. 20:6682–6696. 2014. View Article : Google Scholar : PubMed/NCBI
9	Rana C, Piplani H, Vaish V, Nehru B and Sanyal SN: Downregulation of PI3-K/Akt/PTEN pathway and activation of mitochondrial intrinsic apoptosis by Diclofenac and Curcumin in colon cancer. Mol Cell Biochem. 402:225–241. 2015. View Article : Google Scholar : PubMed/NCBI
10	Rashid K and Sil PC: Curcumin enhances recovery of pancreatic islets from cellular stress induced inflammation and apoptosis in diabetic rats. Toxicol Appl Pharmacol. 282:297–310. 2015. View Article : Google Scholar : PubMed/NCBI
11	Toden S, Okugawa Y, Jascur T, Wodarz D, Komarova NL, Buhrmann C, Shakibaei M, Boland CR and Goel A: Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. Carcinogenesis. 36:355–367. 2015. View Article : Google Scholar : PubMed/NCBI
12	Seo BR, Min KJ, Cho IJ, Kim SC and Kwon TK: Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability. PLoS One. 9:e955882014. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	El-Deiry WS: The role of p53 in chemosensitivity and radiosensitivity. Oncogene. 22:7486–7495. 2003. View Article : Google Scholar : PubMed/NCBI
15	Aylon Y and Oren M: Living with p53, dying of p53. Cell. 130:597–600. 2007. View Article : Google Scholar : PubMed/NCBI
16	Bai N, Zhang C, Liang N, Zhang Z, Chang A, Yin J, Li Z, Luo N, Tan X, Luo N, et al: Yes-associated protein (YAP) increases chemosensitivity of hepatocellular carcinoma cells by modulation of p53. Cancer Biol Ther. 14:511–520. 2013. View Article : Google Scholar : PubMed/NCBI
17	Vousden KH and Prives C: Blinded by the light: The growing complexity of p53. Cell. 137:413–431. 2009. View Article : Google Scholar : PubMed/NCBI
18	Zhou X, Tolstov Y, Arslan A, Roth W, Grüllich C, Pahernik S, Hohenfellner M and Duensing S: Harnessing the p53-PUMA Axis to overcome DNA damage resistance in renal cell carcinoma. Neoplasia. 16:1028–1035. 2014. View Article : Google Scholar : PubMed/NCBI
19	Harris SL and Levine AJ: The p53 pathway: Positive and negative feedback loops. Oncogene. 24:2899–2908. 2005. View Article : Google Scholar : PubMed/NCBI
20	Laptenko O and Prives C: Transcriptional regulation by p53: One protein, many possibilities. Cell Death Differ. 13:951–961. 2006. View Article : Google Scholar : PubMed/NCBI
21	Ma Y, Yang Y, Wang F, Wei Q and Qin H: Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int J Cancer. 137:2275–2286. 2015. View Article : Google Scholar : PubMed/NCBI
22	Piccolo S, Dupont S and Cordenonsi M: The biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev. 94:1287–1312. 2014. View Article : Google Scholar : PubMed/NCBI
23	Barron DA and Kagey JD: The role of the Hippo pathway in human disease and tumorigenesis. Clin Transl Med. 3:252014. View Article : Google Scholar : PubMed/NCBI